Lamivudine is Not Effective in Primary Sjögren's Syndrome

Overview

Journal Ann Rheum Dis

Specialty Rheumatology

Date 2005 Feb 15

PMID 15708886

Citations 2

Authors

B Gescuk

A J Wu

J P Whitcher

T E Daniels

S Lund

K Fye

J C Davis Jr

Affiliations

Soon will be listed here.

Abstract

Background: Retroviral infection has been implicated in the pathogenesis of primary Sjögren's syndrome.

Objective: To examine the efficacy of the reverse transcriptase inhibitor lamivudine in patients with this syndrome.

Methods: 16 patients with primary Sjögren's syndrome were randomised to receive either lamivudine 150 mg twice daily or placebo for three months. Measures of lacrimal and salivary function, including minor salivary gland biopsies, were obtained before and after treatment.

Results: Treatment with lamivudine did not result in significant improvement in the primary outcome measure of unstimulated whole salivary flow or other secondary measures, including minor salivary gland biopsy focus scores.

Conclusion: Lamivudine is not effective in patients with primary Sjögren's syndrome, suggesting either that a retroviral aetiology is not present or that it may be important only in early disease.

Citing Articles

Human Endogenous Retroviruses (HERVs) and Autoimmune Rheumatic Disease: Is There a Link?.

Tugnet N, Rylance P, Roden D, Trela M, Nelson P Open Rheumatol J. 2013; 7:13-21.

PMID: 23750183 PMC: 3636489. DOI: 10.2174/1874312901307010013.

Is Sjögren's syndrome a retroviral disease?.

Sipsas N, Gamaletsou M, Moutsopoulos H Arthritis Res Ther. 2011; 13(2):212.

PMID: 21489323 PMC: 3132012. DOI: 10.1186/ar3262.

References

Tiplady B, Jackson S, Maskrey V, Swift C . Validity and sensitivity of visual analogue scales in young and older healthy subjects. Age Ageing. 1998; 27(1):63-6. DOI: 10.1093/ageing/27.1.63. View

Steinfeld S, Demols P, van Vooren J, Cogan E, Appelboom T . Zidovudine in primary Sjögren's syndrome. Rheumatology (Oxford). 1999; 38(9):814-7. DOI: 10.1093/rheumatology/38.9.814. View

Guggenbuhl P, Jean S, Jego P, Grosbois B, Chales G, Semana G . Primary Sjögren's syndrome: role of the HLA-DRB1*0301-*1501 heterozygotes. J Rheumatol. 1998; 25(5):900-5. View

Papas A, Fernandez M, Castano R, Gallagher S, Trivedi M, Shrotriya R . Oral pilocarpine for symptomatic relief of dry mouth and dry eyes in patients with Sjögrens syndrome. Adv Exp Med Biol. 1998; 438:973-8. DOI: 10.1007/978-1-4615-5359-5_139. View

Humphreys-Beher M, Brayer J, Yamachika S, Peck A, Jonsson R . An alternative perspective to the immune response in autoimmune exocrinopathy: induction of functional quiescence rather than destructive autoaggression. Scand J Immunol. 1999; 49(1):7-10. DOI: 10.1046/j.1365-3083.1999.00490.x. View

Zumla A, Mathur M, Stewart J, Wilkinson L, Isenberg D . T cell receptor expression in Sjögren's syndrome. Ann Rheum Dis. 1991; 50(10):691-3. PMC: 1004532. DOI: 10.1136/ard.50.10.691. View

Sawada S, Sugai S, Iijima S, Takei M, Paredes E, Hayama T . Increased soluble CD4 and decreased soluble CD8 molecules in patients with Sjögren's syndrome. Am J Med. 1992; 92(2):134-40. DOI: 10.1016/0002-9343(92)90103-i. View

Eguchi K, Matsuoka N, Ida H, Nakashima M, Sakai M, Sakito S . Primary Sjögren's syndrome with antibodies to HTLV-I: clinical and laboratory features. Ann Rheum Dis. 1992; 51(6):769-76. PMC: 1004744. DOI: 10.1136/ard.51.6.769. View

Leroy J, Pennec Y, Soulier C, Berthelot J, Letoux G, Youinou P . Follow up study of labial salivary gland lesions in primary Sjögren's syndrome. Ann Rheum Dis. 1992; 51(6):777-80. PMC: 1004745. DOI: 10.1136/ard.51.6.777. View

10.

Vitali C, Bombardieri S, Moutsopoulos H, BALESTRIERI G, Bencivelli W, Bernstein R . Preliminary criteria for the classification of Sjögren's syndrome. Results of a prospective concerted action supported by the European Community. Arthritis Rheum. 1993; 36(3):340-7. DOI: 10.1002/art.1780360309. View

11.

Fox P, Datiles M, Atkinson J, Macynski A, Scott J, Fletcher D . Prednisone and piroxicam for treatment of primary Sjögren's syndrome. Clin Exp Rheumatol. 1993; 11(2):149-56. View

12.

Kruize A, Hene R, Kallenberg C, van Bijsterveld O, van der Heide A, Kater L . Hydroxychloroquine treatment for primary Sjögren's syndrome: a two year double blind crossover trial. Ann Rheum Dis. 1993; 52(5):360-4. PMC: 1005050. DOI: 10.1136/ard.52.5.360. View

13.

Jonsson R, Kroneld U, Backman K, Magnusson B, Tarkowski A . Progression of sialadenitis in Sjögren's syndrome. Br J Rheumatol. 1993; 32(7):578-81. DOI: 10.1093/rheumatology/32.7.578. View

14.

Mariette X, Agbalika F, Daniel M, Bisson M, Lagrange P, Brouet J . Detection of human T lymphotropic virus type I tax gene in salivary gland epithelium from two patients with Sjögren's syndrome. Arthritis Rheum. 1993; 36(10):1423-8. DOI: 10.1002/art.1780361015. View

15.

Fox R, Saito I . Criteria for diagnosis of Sjögren's syndrome. Rheum Dis Clin North Am. 1994; 20(2):391-407. View

16.

Terada K, Katamine S, Eguchi K, Moriuchi R, Kita M, Shimada H . Prevalence of serum and salivary antibodies to HTLV-1 in Sjögren's syndrome. Lancet. 1994; 344(8930):1116-9. DOI: 10.1016/s0140-6736(94)90630-0. View

17.

Matsumoto I, Tsubota K, Satake Y, Kita Y, Matsumura R, Murata H . Common T cell receptor clonotype in lacrimal glands and labial salivary glands from patients with Sjögren's syndrome. J Clin Invest. 1996; 97(8):1969-77. PMC: 507267. DOI: 10.1172/JCI118629. View

18.

Manoussakis M, Moutsopoulos H . Antimalarials in Sjögren's syndrome--the Greek experience. Lupus. 1996; 5 Suppl 1:S28-30. View

19.

Fox R, Dixon R, Guarrasi V, Krubel S . Treatment of primary Sjögren's syndrome with hydroxychloroquine: a retrospective, open-label study. Lupus. 1996; 5 Suppl 1:S31-6. View

20.

Miyawaki S, Nishiyama S, Matoba K . Efficacy of low-dose prednisolone maintenance for saliva production and serological abnormalities in patients with primary Sjögren's syndrome. Intern Med. 2000; 38(12):938-43. DOI: 10.2169/internalmedicine.38.938. View